Cargando…

Fondaparinux: Should It Be Studied in Patients with COVID-19 Disease?

Detalles Bibliográficos
Autores principales:	Marongiu, Francesco, Barcellona, Doris
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Georg Thieme Verlag KG 2020
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7567638/ https://www.ncbi.nlm.nih.gov/pubmed/33083688 http://dx.doi.org/10.1055/s-0040-1719232

Ejemplares similares

Thrombosis centres and AVKs monitoring in COVID-19 pandemic
por: Barcellona, Doris, et al.
Publicado: (2020)

Portable coagulometer for vitamin K-antagonist monitoring: the patients’ point of view
por: Barcellona, Doris, et al.
Publicado: (2018)

The Fondaparinux Paradox: Fondaparinux-Related Heparin-induced Thrombocytopenia
por: Vadi, Sonali, et al.
Publicado: (2018)

Fondaparinux and bleeding risk in COVID-19: unsolved question
por: Russo, Vincenzo, et al.
Publicado: (2021)

Fondaparinux-associated Thrombocytopenia
por: Malik, Jahanzeb, et al.
Publicado: (2021)

Thromboelastographic monitoring of fondaparinux in surgical patients
por: Martinez, B, et al.
Publicado: (2013)

When Will Fondaparinux Induce Thrombocytopenia?
por: Chen, Li-Yu, et al.
Publicado: (2022)

Design and Synthesis of Neutralizable Fondaparinux
por: Zhang, Liangwei, et al.
Publicado: (2022)

Antithrombotic and Anti-Inflammatory Effects of Fondaparinux and Enoxaparin in Hospitalized COVID-19 Patients: The FONDENOXAVID Study
por: Cardillo, Giuseppe, et al.
Publicado: (2021)

Management of acute coronary syndromes with fondaparinux
por: Wienbergen, Harm, et al.
Publicado: (2007)

The hazard of fondaparinux in non-critically ill patients with COVID-19: Retrospective controlled study versus enoxaparin
por: Prandoni, Paolo, et al.
Publicado: (2020)

Thromboprofilaxys With Fondaparinux vs. Enoxaparin in Hospitalized COVID-19 Patients: A Multicenter Italian Observational Study
por: Russo, Vincenzo, et al.
Publicado: (2020)

Failure of Fondaparinux in Autoimmune Heparin-Induced Thrombocytopenia
por: Sartori, Michelangelo, et al.
Publicado: (2020)

Probable fondaparinux-associated bullous hemorrhagic dermatosis
por: Lovatt, Catherine Anne, et al.
Publicado: (2021)

Effects of low molecular weight heparin and fondaparinux on mortality, hemorrhagic and thrombotic complications in COVID-19 patients
por: Fragkou, Paraskevi C., et al.
Publicado: (2022)

Fondaparinux in the management of patients with ST-elevation acute myocardial infarction
por: Turpie, Alexander GG
Publicado: (2006)

Dermatose bulleuse hémorragique probablement associée au fondaparinux
por: Lovatt, Catherine Anne, et al.
Publicado: (2021)

Fondaparinux: A cornerstone drug in acute coronary syndromes
por: Khan, Mohammed Yunus, et al.
Publicado: (2022)

The clinical course of symptomatic deep vein thrombosis after 3 months of anticoagulant therapy using fondaparinux/edoxaban or fondaparinux/vitamin K antagonist
por: Shimizu, Kazuhiro, et al.
Publicado: (2018)

Fondaparinux vs warfarin for the treatment of unsuspected pulmonary embolism in cancer patients
por: Amato, Bruno, et al.
Publicado: (2016)

Fondaparinux vs warfarin for the treatment of unsuspected pulmonary embolism in cancer patients
por: Abdel-Razeq, Hikmat, et al.
Publicado: (2016)

Fondaparinux is effective for acute portal vein thrombosis in decompensated cirrhotic patients
por: Zhang, Zhi-Hao, et al.
Publicado: (2017)

Fondaparinux and acute coronary syndromes: update on the OASIS 5–6 studies
por: Schiele, François
Publicado: (2010)

Oral fondaparinux: use of lipid nanocapsules as nanocarriers and in vivo pharmacokinetic study
por: Ramadan, Alyaa, et al.
Publicado: (2011)

Fondaparinux–Associated Rectus Sheath Hematoma: Skating on Thin Ice
por: Sabanis, Nikolaos, et al.
Publicado: (2020)

The use of fondaparinux and rituximab for recurrent thrombotic events in antiphospholipid syndrome
por: Sayar, Zara, et al.
Publicado: (2022)

Review of fondaparinux sodium injection for the prevention of venous thromboembolism in patients undergoing surgery
por: Bergqvist, David
Publicado: (2006)

Risk factors for bleeding in patients receiving fondaparinux after colorectal cancer surgery
por: Pak, Jongsung, et al.
Publicado: (2018)

Recurrent thrombosis rescued by fondaparinux in high‐risk patients: A case series
por: Tanguay, Mégane, et al.
Publicado: (2022)

Comparative study of the effect of rivaroxaban and fondaparinux on monocyte’s coagulant activity and cytokine release
por: Laurent, Marc, et al.
Publicado: (2014)

Spontaneous acute subdural hematoma due to fondaparinux: Report of two cases
por: Fryburg, Karsten, et al.
Publicado: (2011)

Fondaparinux: another potential treatment for heparin-induced thrombocytopenia type II?
por: Honore, Patrick M., et al.
Publicado: (2016)

Fondaparinux in heparin‐induced thrombocytopenia: A decade's worth of clinical experience
por: Schindewolf, Marc
Publicado: (2018)

Silver-assisted gold-catalyzed formal synthesis of the anticoagulant Fondaparinux pentasaccharide
por: Walke, Gulab, et al.
Publicado: (2021)

Management of Heparin-Induced Thrombocytopenia with Fondaparinux in a Patient with Left Ventricular Assist Device
por: Velagic, V., et al.
Publicado: (2014)

Postoperative decreased levels of D-dimer in patients with gynecologic cancer with enoxaparin and fondaparinux thromboprophylaxis
por: KODAMA, JUNICHI, et al.
Publicado: (2013)

Fondaparinux in a critically Ill patient with heparin-induced thrombocytopenia: A case report
por: He, Yumiao, et al.
Publicado: (2018)

Effectiveness of Fondaparinux in the Japanese Population with Acute Venous Thromboembolism -A Study Comparing Patients with and without Cancer-
por: Yamashita, Asami, et al.
Publicado: (2022)

Use of fondaparinux in a pregnant woman with pulmonary embolism and heparin-induced thrombocytopenia
por: Ciurzyński, Michał, et al.
Publicado: (2011)

Systematic review of fondaparinux for heparin‐induced thrombocytopenia: When there are no randomized controlled trials
por: Linkins, Lori‐Ann, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_qqkkaeh3a9mj7428auh3h0pmgn